MicroRNA inhibitor therapy in systemic lupus erythematosus
US12016314B2 · kind B2 · utility
0Cited by
110References
3Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Sep 10, 2018 |
| Grant date | Jun 25, 2024 |
| Priority date | — |
| Expiry date | Jul 1, 2040 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2310/3231
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Disclosed are novel compositions and methods for treating systemic lupus erythematosus (SLE) as well as a model for measuring the efficacy of said treatments. Specifically, the disclosure provides a non-human animal model for SLE comprising a severe combined immunodeficient non-human animal comprising exogenous cells from a human subject with SLE, wherein the cells from the human subject are peripheral blood mononuclear cells. Further disclosed is a method of screening for a drug candidate that inhibits or reduces SLE using a severe combined immunodeficient non-human animal.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.